T Cell Receptor Excision Circles (TREC), Molecular Analysis
T-cell receptor excision circles (TRECs) are small circles of DNA created in T-cells during their passage through the thymus as they rearrange their TCR genes. The presence of TRECs indicates T-cell maturation. TRECs are stable and do not duplicate during mitosis and are therefore diluted as mature T-cells proliferate. The number of TRECs per T-cell reflects the number of naïve T-cells produced by the thymus and therefore can be used as a biomarker for autologous T-cell production. Normal newborns have 1 TREC per 10 T-cells reflecting a high number of naïve T-cells that have not proliferated. Older children and adults have 1 TREC per 100 and 1 per 1000 T-cells respectively.
TRECs may be lower than normal for age in both inherited and acquired immunodeficiency states. In AIDS, TRECs may be low and can be restored by antiretroviral treatment. TRECs are also reduced in patients after chemotherapy and stem cell transplantation and increasing numbers of TRECs indicate hematopoietic reconstitution.
Peripheral blood TREC’s can also be used to screen infants for inherited immunodeficiency disorders. In patients with DiGeorge Syndrome (congenital absence of the thymus) there are no detectable TRECs. Similarly, TRECs can be measured in newborns to screen for Severe Combined Immunodeficiency Syndrome (SCIDS). However, it is important to note that immunodeficiencies due to pure B-cell, neutrophil, complement factor or other disorders that do not impact T-cell development will not be detected by TREC screening
- For measuring T-cell output or reconstitution (thymopoiesis) following hematopoietic cell transplantation or highly active antiretroviral therapy
- To evaluate thymic function in patients with cellular or combined primary immunodeficiencies, or receiving immunotherapy or cancer vaccines
- For assessing T- Cell recovery following thymus transplants for DiGeorge Syndrome
T-cell receptor excision circles (TRECs) are evaluated based on an appropriate age-related reference values and generally it shows an inverse correlation with age.
Infants with SCID may lack or low number of TRECs. During hematopoietic cell transplantation (HCT), highly active antiretroviral therapy (HAART), thymic transplants, etc, TREC typically increases from absent or very low levels (below age-matched reference range) to baseline levels or exceeds baseline levels, showing evidence of thymic rebound, which is consistent with recovery of thymic output and T cell reconstitution.
The thymic post-transplant can be compared with pre-transplant (prior to myeloablative or non-myeloablative conditioning) or a pre-treatment baseline specimen to monitor the treatment.
Normal (infant blood samples) - ≥6794 TREC copies/106 CD3 T cells or 14 to 474 copies/μL blood
Real-Time quantitative polymerase chain reaction (PCR), conventional sequencing, next generation sequencing.
Whole Blood.
Stability
- Ambient- 48 hours
- Refrigerated: 3-5 days
- Clin Exp Immunol. 2018 Feb;191(2):198-202. [PMID: 28976005]
- J Mol Diagn. 2017;19:755-765. [PMID: 28826609]
- BMC Infect Dis. 2017 Jan 5;17(1):18. [PMID: 28056841]
- J Clin Immunol. 2017 Jan;37(1):51-60. [PMID: 27873105]
- Methods Mol Biol. 2013;979:147-59. [PMID: 23397394]
- Curr Opin Allergy Clin Immunol. 2011 Dec;11(6):517-24. [PMID: 21971333]
- Pediatr Res. 2010 Feb;67(2):211-6. [PMID: 19858778]